ACADIA Pharmaceuticals (ACAD) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organon (OGN) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 30.1% versus a loss of 8.8%. Over five years, ACAD leads with a +12.2% price change compared with -60.5% for OGN. Organon is the larger company by market cap ($3.62 billion vs $3.41 billion), about 1.1 times the size, while ACADIA Pharmaceuticals is growing revenue faster (+11.9% vs -2.9%).
On valuation, Organon trades at a lower forward P/E (3.8x vs 22.3x for ACADIA Pharmaceuticals). Organon pays a dividend yielding 0.58%, while ACADIA Pharmaceuticals does not currently pay one. ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus 3.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | OGN |
|---|---|---|
| Share price | $19.77 | $13.80 |
| Market cap | $3.41B | $3.62B |
| 1-day change | +0.61% | +0.04% |
| YTD return | -26.43% | +92.33% |
| 1-year return | -8.77% | +30.09% |
| 5-year return | +12.22% | -60.48% |
| P/E ratio (TTM) | 8.87 | 17.69 |
| Forward P/E | 22.25 | 3.82 |
| EPS (TTM) | $2.23 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | $1.07B | $6.22B |
| Revenue growth (YoY) | +11.87% | -2.92% |
| Net income (latest FY) | $391.00M | $187.00M |
| Gross margin | 91.69% | 53.30% |
| Operating margin | 9.78% | — |
| Net margin | 36.49% | 3.01% |
| 52-week high | $30.96 | $13.80 |
| 52-week low | $19.32 | $5.69 |
| Distance from 52-week high | -36.14% | -0.04% |
| Analyst consensus | buy | none |
| Avg. price target upside | +62.67% | -18.45% |
| Average volume | 1.84M | 2.64M |
| Shares outstanding | 172.31M | 262.61M |
| Employees | 796 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGN has outperformed ACAD by 38.9 percentage points over the past year.
- Organon trades at a higher earnings multiple (17.7x vs 8.9x trailing P/E).
- ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus 3.0 cents for Organon.
- ACADIA Pharmaceuticals grew revenue faster in its latest fiscal year (+11.87% vs -2.92%).
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
ACAD vs OGN FAQ
Which is bigger, ACADIA Pharmaceuticals or Organon?
Organon (OGN) is larger, with a market capitalization of $3.62B compared with $3.41B for ACADIA Pharmaceuticals (ACAD).
Which stock has performed better over the past year, ACAD or OGN?
OGN returned +30.09% over the past 12 months, compared with -8.77% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ACAD or OGN?
ACAD has the lower trailing P/E at 8.9, versus 17.7 for OGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, ACADIA Pharmaceuticals or Organon?
Organon pays a dividend yielding 0.58%, while ACADIA Pharmaceuticals does not currently pay a regular dividend.
Are ACADIA Pharmaceuticals and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.